Disease Landscape and Forecast Insights

Glomerulonephritis (GN) is a broad term covering various conditions involving injury and inflammation of the glomerulus, which plays an important role in the filtration of blood in the kidney. As…

Trigeminal neuralgia (TN) is a rare and painful disorder, usually triggered by innocuous stimuli, resulting in paroxysmal neuropathic facial pain in the regions served by the trigeminal nerve…

Hormonal therapies have dominated the treatment of prostate cancer for the past decade. Zytiga (Janssen, generics) and Xtandi (Medivation / Astellas Pharma), initially approved for metastatic…

The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the…

A variety of analgesic products are available to specialists managing postoperative pain in the United States, although the majority of these medicines are available as inexpensive generics…

Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for NHL…

MARKET OUTLOOK The current treatment algorithm for NSCLC is dominated by targeted branded therapies, reflecting its biomarker-driven treatment landscape. The EGFR and ALK TKIs Tagrisso and…

The treatment landscape for NSCLC continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies into new patient populations. Examples include…

The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with…

Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) market. Most inpatients are successfully treated empirically with such agents, making it difficult for…

The treatment of osteoporosis represents a large market that is dominated by the bisphosphonate drug class. Although more-efficacious therapies are available, step therapy is commonplace, with…

Chemotherapy remains the standard of care for the treatment of ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and, more recently, PARP inhibitors have entered the…